Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Australian Clinical Labs Ltd ( (AU:ACL) ) just unveiled an update.
Australian Clinical Labs Limited has continued its on-market share buy-back program for its ordinary fully paid shares, as disclosed in its latest daily notification to the ASX. The update notes that the company has repurchased a cumulative 8,838,877 shares prior to the previous day, with an additional 107,341 shares bought back on the previous trading day.
This ongoing buy-back activity indicates that the company is actively reducing its share count, which can signal confidence in its valuation and may enhance earnings per share over time. The continued execution of the program is relevant for shareholders monitoring capital management, market liquidity of ACL shares, and the company’s approach to returning value to investors.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.20 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited operates in the healthcare diagnostics sector, providing pathology and laboratory testing services. The company is listed on the ASX under the code ACL, with ordinary fully paid shares as its primary listed security.
Average Trading Volume: 751,730
Technical Sentiment Signal: Sell
Current Market Cap: A$361M
Find detailed analytics on ACL stock on TipRanks’ Stock Analysis page.